EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report

Man Wu, Lin Huang, Yibin Yao, Yuling Xu, Yang Yang, Jun Luo, Zhenfang Liu

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06522-8 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Man Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Chromosomes, Human, Pair 8, Myeloproliferative Disorders, Oncogene Proteins, Fusion, Protein Kinase Inhibitors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, the Guangxi Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

8p11 myeloproliferative syndrome (EMS) is a rare aggressive hematologic malignancy with a poor prognosis that can rapidly develop into acute leukemia. It is characterized by the translocation of fibroblast growth factor receptor-1 (FGFR1), and there is still a lack of effective and reliable treatment methods at present. This report provides a new therapeutic strategy for EMS patients diagnosed with BCR-FGFR1 fusion. This report describes a case of EMS patient with a positive BCR-FGFR1 fusion gene, whose manifestations are similar to those of chronic myeloid leukemia (CML). After diagnosis by fluorescence in situ hybridization (FISH) and RNA sequencing (RNA-seq), olverembatinib, the third-generation tyrosinase inhibitor (TKI) developed in China, was used for treatment. After monotherapy and follow-up for more than one year, partial molecular response (PR) was achieved. During this period, hematologic remission and cytogenetic remission were achieved. The treatment safety of the entire process was excellent. In summary, olverembatinib provides more treatment options for rare diseases such as 8p11 myeloproliferative syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chromosomes, Human, Pair 8Myeloproliferative DisordersOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-bcrReceptor, Fibroblast Growth Factor, Type 1HumansMaleMiddle Aged

Stichwörter der Autor:innen

8p11 myeloproliferative syndromeEMSFGFR1Olverembatinib

Substanzen

FGFR1 protein, humanOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-bcrReceptor, Fibroblast Growth Factor, Type 1

Autor:innen und Institutionen

  • Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
  • Hematology Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. liuzhenfang@gxmu.edu.cn.
  • Key Laboratory of Hematology, Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, Education, Nanning, Guangxi, China. liuzhenfang@gxmu.edu.cn.

Förderung

  • the National Natural Science Foundation of China
  • the Guangxi Natural Science Foundation

Zitieren

APA

Wu, M., Huang, L., Yao, Y., Xu, Y., Yang, Y., Luo, J., & Liu, Z. (2025). Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report. Annals of Hematology. https://doi.org/10.1007/s00277-025-06522-8

Vancouver

Wu M, Huang L, Yao Y, Xu Y, Yang Y, Luo J, et al. Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report. Annals of Hematology. 2025. doi:10.1007/s00277-025-06522-8

BibTeX
@article{Wu2025,
  author = {Wu, Man and Huang, Lin and Yao, Yibin and Xu, Yuling and Yang, Yang and Luo, Jun and Liu, Zhenfang},
  title = {Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06522-8}
}
Kostenlos starten →